Testosterone Enanthate in Children Under 12: Transitioning to Adult Care

Who Actually Receives Testosterone Enanthate Before Age 12

Testosterone enanthate prescriptions in children under 12 are rare. The two conditions that drive most use are primary hypogonadism (absent or non-functional testes, as in Klinefelter syndrome or bilateral anorchia) and secondary hypogonadism from pituitary or hypothalamic pathology. A smaller subset involves constitutional delay of growth and puberty when watchful waiting has been exhausted and psychological burden is severe.

Primary vs. Secondary Hypogonadism in This Age Group

Primary hypogonadism in a child under 12 produces persistently low serum testosterone alongside elevated LH and FSH. The 2018 Endocrine Society Clinical Practice Guidelines on Male Hypogonadism define biochemical hypogonadism in this context as morning testosterone below the age-specific reference interval on at least two separate measurements, with gonadotropin levels confirming the defect's anatomical location [1].

Secondary hypogonadism, by contrast, shows low testosterone with low or inappropriately normal gonadotropins. This pattern requires MRI of the hypothalamic-pituitary axis before initiating any androgen therapy [2].

Constitutional Delay of Growth and Puberty

CDGP is the most common cause of delayed puberty, accounting for roughly 60% of cases in referred boys [3]. Most pediatric endocrinologists manage CDGP with watchful waiting first. When a child under 12 has bone age significantly behind chronological age and measurable psychosocial distress, a short course of low-dose testosterone enanthate (25 mg IM every 4 weeks for 3-6 months) may be used to prime the hypothalamic-pituitary-gonadal axis without causing irreversible virilization [4].

FDA Approval Status and Off-Label Realities

Testosterone enanthate (Delatestryl and generics) carries FDA approval for conditions associated with testosterone deficiency in males. The approved label does not specify pediatric dosing for children under 12 in detail [5]. Prescribing in this age group is therefore guided by published clinical practice guidelines and institutional protocols rather than by a specific FDA-approved pediatric indication.

What the Label Says

The FDA-approved prescribing information states that testosterone therapy in pediatric patients "should be undertaken with extreme caution" and that "androgen therapy should be used very cautiously in children" due to risks of premature epiphyseal closure, which can permanently reduce adult height [5]. Bone age assessments every 6 months are explicitly recommended in the label for any pediatric use.

Guidelines Filling the Gap

The Endocrine Society's 2018 guidelines provide the most practical pediatric dosing framework currently available. They recommend starting at 25-50 mg testosterone enanthate IM every 4 weeks, titrating based on pubertal progression, and capping doses below full adult replacement levels until epiphyseal closure is confirmed on imaging [1]. The Pediatric Endocrine Society echoes this approach in their consensus statement on delayed puberty [4].

Dosing Framework for Children Under 12

Dosing testosterone enanthate in a prepubertal child requires matching the rate of virilization to the child's bone age, not chronological age. A child with a bone age of 9 years but a chronological age of 11 years should be dosed relative to the bone age.

Starting Doses and Titration

A typical induction protocol proceeds as follows:

• Months 1-6: 25-50 mg IM every 4 weeks
• Months 7-12: 50-75 mg IM every 4 weeks if pubertal progression is inadequate and bone age permits
• Year 2 and beyond: Dose adjustments toward 100 mg IM every 4 weeks only after Tanner stage II-III is confirmed and bone age review supports continued therapy

Serum testosterone measured 7 days post-injection (the midpoint of the dosing interval) should fall within the early-pubertal reference range, roughly 50-200 ng/dL during induction, not the adult male range of 300-1,000 ng/dL [1].

Monitoring Parameters at Each Cycle

Every injection cycle should include a clinical assessment of Tanner staging. Every 6 months, the clinician should obtain:

1. Left-hand and wrist X-ray for bone age (Greulich and Pyle atlas)
2. Morning serum total testosterone (drawn 7 days post-injection)
3. LH and FSH (to track endogenous axis suppression)
4. Height velocity calculation from the clinic's growth chart

Hematocrit should be checked at 3 months and 6 months, as even low-dose androgen therapy can stimulate erythropoiesis [6].

Risks Specific to the Under-12 Population

Premature Epiphyseal Closure

This is the dominant concern. Excess androgen exposure accelerates growth plate maturation faster than linear growth, net effect being shorter adult stature. A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that testosterone-induced bone age advancement of more than 1 year per chronological year is associated with adult height below predicted mid-parental height [7]. Strict dose ceilings and 6-month bone age imaging are the only reliable safeguards.

Behavioral and Psychological Effects

Even low doses of exogenous testosterone can produce irritability, increased aggression, and acne in prepubertal children. Parents and caregivers should be counseled at initiation. These effects are generally dose-dependent and reversible upon dose reduction, but they may disrupt school performance and peer relationships before they resolve [3].

Suppression of Endogenous Axis

In children with CDGP (not true hypogonadism), short-course testosterone enanthate is intended to prime, not replace. If therapy continues too long at doses that suppress LH and FSH below detectable levels, the spontaneous pubertal axis may be delayed further. The monitoring protocol described above catches this by tracking gonadotropin levels at each cycle.

Building the Transition-to-Adult-Care Plan

The transition from pediatric to adult endocrinology is not an event. It is a process that begins 2-3 years before the actual transfer of care. The American Academy of Pediatrics defines transition as "a purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented health care systems" [8].

For a child who started testosterone enanthate before age 12, the transition process should begin no later than age 14-15.

Step 1: Establish Transfer Readiness

Transfer readiness encompasses three domains: medical (the adolescent understands the diagnosis and medication), self-management (the adolescent can request refills, identify injection-site complications, and describe emergency signs), and administrative (insurance coverage in the adult system is confirmed). The TRAQ (Transition Readiness Assessment Questionnaire) is a validated tool for assessing readiness in adolescents with chronic conditions and can be used in this population [9].

Step 2: Re-Confirm the Diagnosis in the Adult Framework

Before the handoff, the pediatric team should re-evaluate whether the original diagnosis remains valid. A child treated for CDGP who has now completed spontaneous puberty may no longer need testosterone enanthate at all. A child with confirmed primary hypogonadism (e.g., Klinefelter syndrome, 47,XXY) will need lifelong therapy, but the adult endocrinologist should confirm this with a fresh biochemical assessment, not simply inherit the childhood diagnosis without review [1].

Klinefelter syndrome affects approximately 1 in 650 male births and is the most common genetic cause of primary hypogonadism requiring long-term testosterone therapy [10]. These patients represent the majority of pediatric cases that carry into adult care.

Step 3: The Structured Transfer Letter

The pediatric team should produce a comprehensive transfer document that includes:

• Original diagnosis with supporting lab values and imaging
• Cumulative testosterone enanthate dose history and all formulation changes
• Growth chart with adult height prediction
• Bone age series with dates and findings
• Current injection schedule, dose, and lot number of last medication
• Any adverse events, including hematocrit elevations or behavioral concerns
• Contact information for the pediatric provider for at least 12 months post-transfer

The Endocrine Society's 2018 guidelines specifically recommend that transition documentation include "a complete summary of prior treatment, growth data, and bone health assessment" [1].

Step 4: Overlap Period

A minimum 6-month overlap period, during which both the pediatric and adult providers are actively involved, reduces the risk of medication gaps and allows the adult provider to establish independent clinical judgment about the patient. During this period the adolescent should attend at least one appointment with each provider independently, building the adult-patient relationship before the pediatric relationship formally closes [8].

Step 5: Adult Dosing Recalibration

Adult testosterone replacement targets differ from pediatric induction targets. Once epiphyseal closure is confirmed (typically by Tanner V and a stable bone age on X-ray), the adult endocrinologist will adjust the dose to target mid-normal adult male serum testosterone. For testosterone enanthate, this commonly means 100-200 mg IM every 1-2 weeks, calibrated so that the trough (just before the next injection) remains above 300 ng/dL and the peak (24-48 hours post-injection) stays below 1,100 ng/dL [1]. The pediatric low-dose induction regimen should not simply be continued unchanged into adulthood.

Special Populations Within the Under-12 Cohort

Klinefelter Syndrome (47,XXY)

Boys with Klinefelter syndrome often present in middle childhood with subtle findings. Testosterone production typically declines progressively through puberty as testicular Leydig cell function fails. A 2019 study in the European Journal of Endocrinology (N=167) found that 64% of adolescents with Klinefelter syndrome required testosterone replacement by age 14 [11]. These patients need the transition-to-adult-care pathway outlined above plus fertility counseling before the adult transfer, as fertility options are time-sensitive.

Bilateral Anorchia

Boys born without functional testes (vanishing testes syndrome) have no endogenous testosterone production from birth. These children are started on testosterone enanthate earlier than most and require lifelong uninterrupted therapy. The transition plan for this group is essentially a permanent prescription handoff with no possibility of treatment discontinuation at any life stage.

Post-Chemotherapy Hypogonadism

Gonadotoxic chemotherapy regimens (particularly alkylating agents such as cyclophosphamide) can destroy Leydig cell function in young children. A 2021 JAMA Oncology analysis of 2,520 childhood cancer survivors found that 17% of male survivors had primary hypogonadism by age 18 [12]. Oncology survivorship clinics often manage these patients alongside endocrinology, and the transition plan must include the oncology team's long-term follow-up schedule.

Practical Injection Guidance for Caregivers

Children under 12 depend on parents or caregivers for IM injections. Testosterone enanthate is an oil-based depot preparation, delivered into the gluteal or vastus lateralis muscle using a 22-25 gauge needle appropriate for the child's muscle mass. The vastus lateralis (outer thigh) is preferred in younger children because it is more accessible for self-injection training as the child matures.

Caregivers should rotate injection sites to reduce the risk of local fibrosis. The injection site should be inspected at each clinic visit. Oil emboli, though rare, have been reported with inadvertent intravascular injection. Z-track technique is standard [5].

Vial storage at room temperature (below 30 degrees C) and protection from light are required. Testosterone enanthate solution should be clear to pale yellow. Any cloudiness or particulate matter is a reason to discard the vial and contact the pharmacy.

What Adult Endocrinologists Need to Know at First Visit

The first adult endocrinology visit for a patient transferring from pediatric care should accomplish four things:

1. Review the transfer summary and independently verify the diagnosis
2. Order a fresh biochemical panel: total testosterone (morning), LH, FSH, complete blood count, and metabolic panel
3. Assess bone density by DXA scan if cumulative testosterone exposure has been greater than 3 years, as androgen therapy affects trabecular bone density even at pediatric doses [13]
4. Confirm the patient's own understanding of the diagnosis and long-term treatment plan

The adult provider should not simply continue the pediatric dose. Recalibration to adult targets is standard of care. The Endocrine Society states that "the goal of testosterone therapy in hypogonadal men is to restore serum testosterone concentrations to the mid-normal range for young healthy men" [1].

A baseline PSA is not warranted in patients under 18 at first adult visit but should be added to the monitoring panel at age 40 per standard adult male hypogonadism surveillance protocols.